ClinicalTrials.gg
RecruitingNCT06240143MARIANEUpdated Nov 14, 2024

Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma

A Phase 1/2 interventional study of Ipilimumab and Nivolumab in Melanoma, sponsored by The Netherlands Cancer Institute. Recruiting at 6 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-14.

Sponsored by The Netherlands Cancer Institute · Phase 1/2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
96
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 155 studies testing ipilimumab in Melanoma — 21 open to participants now, 42 under way, 5 of them phase 3. Ipilimumab · Melanoma.

Planned enrollment
35th of 152
96 · median 30
Started
2024
with 4 others
Phase 1/2
19 of 155
5 open now
Primary completion
2029-07
later than 36 of 41 live
Registered
139th of 155
by date
Lead sponsor
4 of 155
The Netherlands Cancer Institute

Among the 155 studies testing ipilimumab in Melanoma, this one is the 35th largest by planned enrollment of the 152 interventional ones that give a count, is one of 5 that started in 2024, is one of 19 in phase 1/2, reaches primary completion later than 36 of the 41 other live ones, and was the 139th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

21 of the 155 studies testing ipilimumab in Melanoma are open now, in 9 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About ipilimumab

Ipilimumab: first FDA approval 2011 (YERVOY), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies testing ipilimumab in Melanoma, or all of them as a file.
02

Study summary

This open label, single country trial will test if local injection of low-dose ipilimumab and nivolumab, is safe and reduces the sentinel node positivity in high-risk stage II melanoma patients.

03

Conditions studied

  • Melanoma

Browse trials for

Keywords

  • neoadjuvant
  • intradermal
  • immunotherapy
  • checkpoint inhibitors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women, at least 18 years of age;
  • World Health Organization (WHO) Performance Status 0 or 1;
  • confirmed, stage pT3-4 cutaneous melanoma (Breslow thickness >2.0mm; according to AJCC criteria 8th edition);
  • Having ≥44% risk for SN positivity as assessed by the MIA Sentinel Node Risk prediction tool (melanomarisk.org.au/SNLForm)1;
  • Excision of primary melanoma took place ≤4 weeks prior to ;
  • Naïve for re-excision of the primary melanoma site and for sentinel node procedure;
  • No other solid, distantly metastasized , no hematological malignancies and no malignancies for which systemic treatment is administered within 6 months prior to study inclusion;
  • No prior immunotherapy targeting , PD-1, PD-L1 or LAG-3;
  • No prior targeted therapy with BRAF/MEK inhibition;
  • No medications within 6 months prior to study inclusion ( equivalent to prednisolone ≤10 mg are allowed);
  • Screening laboratory values must meet the following criteria: WBC ≥2.0x109/L, neutrophils ≥1.5x109/L, ≥100x109/L, ≥5.5 mmol/L, creatinine ≤1.5xupper limit of normal (), ≤1.5x ULN, ALT ≤1.5x ULN, ≤1.5x ULN (except for subjects with Gilbert syndrome who must have a total bilirubin \<3.0 mg/dL)
  • LDH level ≤ULN;
  • Women of (WOCP) must use appropriate method(s) of , i.e. methods with a failure rate of \<1% per year when used consistently and correctly, to avoid pregnancy for 23 weeks post last ipilimumab + nivolumab infusion;
  • Patient willing and able to understand the protocol requirements and comply with the treatment schedule, scheduled visits, electronic patient outcome reporting, tumor and extra blood withdrawal during screening, and other requirements of the study;

Exclusion criteria

Exclusion Criteria:

  • Acral, uveal/ocular, mucosal or or lentigo maligna melanoma;
  • A concurrent second, primary melanoma;
  • Regionally or distantly metastasized melanoma, including in-transit and macroscopic lymph node metastases;
  • No suspect lymph nodes detectable by ultrasound in the draining lymph node region(s);
  • Subjects with any active disease or a documented history of autoimmune disease, or history of syndrome that required systemic or medications. Subjects with resolved childhood asthma/atopy, type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, are permitted to enroll;
  • Prior surgery, including prior sentinel node procedure or lymph node dissection, in the affected lymph node region(s);
  • Prior radiotherapy targeting the affected lymph node region(s);
  • Subjects will be excluded if they test positive for virus surface antigen (HBsAg) or virus ribonucleic acid (HCV antibody), indicating acute or chronic infection. Subjects treated and being at least one year free from HCV are allowed to participate;
  • Subjects will be excluded if they have known history of testing positive for (HIV) or known acquired immunodeficiency syndrome (AIDS);
  • Subjects with history of allergy to study drug components or history of severe reaction to monoclonal antibodies;
  • Subjects with underlying medical conditions or active infection that, in the investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events;
  • Women who are pregnant or breastfeeding;
  • Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids >10 mg prednisolone daily equivalent;
  • Use of other drugs before study drug administration 30 days or 5 half-times before study inclusion;
  • Psychological, familial, sociological, or geographical conditions that potentially hamper compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before registration in the trial.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    A: 2x low dose intradermal

    2 cycles of intradermal ipilimumab 0.5 mg + nivolumab 1 mg every 3 weeks

    Drug: Ipilimumab · Drug: Nivolumab

  • Experimental
    B: 6x low dose intradermal

    6 cycles of intradermal ipilimumab 0.5 mg + nivolumab 1 mg every week

    Drug: Ipilimumab · Drug: Nivolumab

  • Experimental
    C: 2x higher dose intradermal

    2 cycles of intradermal ipilimumab 10 mg + nivolumab 20 mg every 3 weeks

    Drug: Ipilimumab · Drug: Nivolumab

  • Experimental
    D: intradermal + intravenous

    intradermal ipilimumab + nivolumab according to the optimal intradermal regimen plus 2 cycles of intravenous nivolumab 240mg every 3 weeks

    Drug: Ipilimumab · Drug: Nivolumab

Interventions

06

What researchers measure

Primary outcomes

  1. Feasibility of application of studytreatment

    Feasibility as measured by the adherence to the timelines in the study protocol. A treatment arm will be declared as not feasible if 3/11 or 6/24 patients cannot adhere to the planned time of surgery due to treatment-related adverse events.

    Time frame: Up to 100 days after treatment

  2. Rate of effectiveness of the studytreatment

    Pathological response as assessed by blinded central review, adapted from the INMC criteria, including pCR, near-pCR, or pPR (0-50% residual viable tumor in resection material), or sentinel node negativity for melanoma.

    Time frame: Up to 5 years after randomization

Secondary outcomes

  1. treatment-related adverse events

    Frequency and duration of all grade and grade 3-5, treatment-related adverse events according to CTCAE 5.0;.

    Time frame: Up to 5 years after randomization

  2. EFS

    defined as time from start of treatment to melanoma progression (irresectable stage II or III, or stage IV disease), melanoma recurrence, treatment-related death, or melanoma-related death, whichever occurs first;

    Time frame: Up to 5 years after start of treatment

  3. DMFS

    defined as time between date of surgery (re-excision and SN-procedure) and date of first distant metastasis, treatment-related death or melanoma-related death, whichever occurs first;

    Time frame: Up to 5 years after randomization

  4. OS

    defined as time between date of start of treatment and date of death;

    Time frame: Up to 5 years after start of treatment

07

Study locations

2 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jul 2029, 64 months after the start.

Of 85 non-industry phase 1/2 interventional studies under Melanoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 98. This study's planned 64 months is close to that.

Counting every sponsor, half of 220 studies reached it within 60 months; a quarter within 42 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2024
First posted
Feb 2, 2024
StartActual
Mar 8, 2024
Primary completionEst.
Jul 2029
CompletionEst.
Mar 2034
Last update
Nov 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06240143
Responsible party
Sponsor
First posted
Feb 2, 2024
Start date
Mar 8, 2024
Primary completion
Jul 2029 (estimated)
Completion
Mar 2034 (estimated)
Last update
Nov 14, 2024

Study contacts

Christian Blank, Prof
Contact
c.blank@nki.nl
+31205129111
Christian Blank, Prof
principal investigator · Medical oncologist/researcher

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ipilimumab · Nivolumab

Start the discussion